P
Protalix Biotherapeutics Inc
F:PBDA
Protalix Biotherapeutics Inc
F:PBDA
Price:
2.44
EUR
0.83%
Market Closed
Market Cap:
€178.9m
Relative Value
The Relative Value of one PBDA stock under the Base Case scenario is 4.13 EUR. Compared to the current market price of 2.44 EUR, Protalix Biotherapeutics Inc is Undervalued by 41%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PBDA
Relative Value
Base Case
4.13
EUR
Undervaluation 41%
P
Multiples Across Competitors
PBDA Competitors Multiples
Protalix Biotherapeutics Inc Competitors
Protalix Biotherapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
P
|
Protalix Biotherapeutics Inc
F:PBDA
|
231.2m EUR | 3.6 | 36 | 20.3 | 23.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
404.2B USD | 6.6 | 96.3 | 15.8 | 21.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.5B USD | 5.5 | 26.3 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.8B USD | 6.2 | 21.6 | 13.4 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.7B USD | 10.4 | 31.6 | 23.9 | 25 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.8 | 18.4 | 13.8 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.7B AUD | 3.2 | 34.9 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.2B EUR | 11 | 35.2 | 38.3 | 39.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
